$13.20
1.11% today
Nasdaq, Apr 03, 06:50 pm CET
ISIN
US82835W1080
Symbol
SPRY
Sector
Industry

Silverback Therapeutics Stock price

$13.05
+2.87 28.19% 1M
-1.40 9.69% 6M
+2.50 23.70% YTD
+3.77 40.63% 1Y
+9.81 302.78% 3Y
-7.95 37.86% 5Y
-7.95 37.86% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.52 4.15%
ISIN
US82835W1080
Symbol
SPRY
Sector
Industry

Key metrics

Market capitalization $1.28b
Enterprise Value $966.48m
P/E (TTM) P/E ratio 170.14
EV/FCF (TTM) EV/FCF 74.40
EV/Sales (TTM) EV/Sales 10.84
P/S ratio (TTM) P/S ratio 14.36
P/B ratio (TTM) P/B ratio 4.98
Revenue growth (TTM) Revenue growth 297,063.33%
Revenue (TTM) Revenue $89.15m
EBIT (operating result TTM) EBIT $-3.08m
Free Cash Flow (TTM) Free Cash Flow $12.99m
Cash position $314.02m
EPS (TTM) EPS $0.08
P/E forward negative
P/S forward 15.41
EV/Sales forward 11.63
Short interest 37.04%
Show more

Is Silverback Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Silverback Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Silverback Therapeutics forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Silverback Therapeutics forecast:

Buy
100%

Financial data from Silverback Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
89 89
297,067% 297,067%
100%
- Direct Costs 1.19 1.19
1,600% 1,600%
1%
88 88
220,000% 220,000%
99%
- Selling and Administrative Expenses 71 71
51% 51%
80%
- Research and Development Expense 20 20
3% 3%
22%
-2.88 -2.88
96% 96%
-3%
- Depreciation and Amortization 0.21 0.21
200% 200%
0%
EBIT (Operating Income) EBIT -3.08 -3.08
95% 95%
-3%
Net Profit 8 8
115% 115%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Silverback Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Silverback Therapeutics Stock News

Positive
Seeking Alpha
14 days ago
ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's competitive edge lies in its innovative intranasal delivery, targeting a $3 billion initial addressable market in the U.S. with potential growth prospects. Despite neffy's potential, risks include co...
Neutral
Seeking Alpha
14 days ago
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz...
Positive
Investors Business Daily
14 days ago
Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics. The post ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move.
More Silverback Therapeutics News

Company Profile

Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson on January 4, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Richard Lowenthal
Employees 160
Founded 2015
Website www.ars-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today